Lycia Therapeutics grants CFO 399,746 stock options

The award begins vesting June 2, 2027, then vests monthly subject to continued service, and expires August 10, 2036.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. reported a grant of 399,746 stock options to Chief Financial Officer and ten percent owner Amy Bachrodt on August 11, 2026. The options have a $3.70 per-share exercise price and expire August 10, 2036.

One-quarter of the award vests June 2, 2027, with an additional 1/48 vesting monthly thereafter, subject to her providing service on each vesting date. The award occurred before the issuer registered a class of equity securities under Section 12 of the Exchange Act in connection with its initial public offering.

Insider Trade Summary

Grant/Award: 399,746 shares

Grant/Award 1 txn

Insider Bachrodt Amy

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	399,746	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 399,746 contracts (Direct)

Footnotes (2)

1. F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
2. F2. The options vest as to 1/4 of the total award on June 2, 2027, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Stock options granted: 399,746 options Exercise price: $3.70 per share First vesting installment: 1/4 of the total award +2 more

5 metrics

Stock options granted 399,746 options Granted August 11, 2026

Exercise price $3.70 per share Stock options granted to Amy Bachrodt

First vesting installment 1/4 of the total award Vests June 2, 2027, subject to service on the vesting date

Subsequent vesting installments 1/48 of the total award monthly Vesting begins after June 2, 2027, subject to service on each vesting date

Expiration date August 10, 2036 Stock options granted to Amy Bachrodt

Key Terms

Stock Option (Right to Buy), Section 12 of the Exchange Act, Rule 16a-2(a)

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Section 12 of the Exchange Act regulatory

"registration of a class of equity securities under Section 12 of the Exchange Act"

Rule 16a-2(a) regulatory

"reported herein pursuant to Rule 16a-2(a)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did LYCA CFO Amy Bachrodt receive?

Amy Bachrodt received a grant of 399,746 stock options on August 11, 2026, with a $3.70 per-share exercise price. The options cover 399,746 shares of common stock and expire August 10, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/26/2026 - 06:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bachrodt Amy

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7	08/11/2026(1)		A		399,746		(2)	08/10/2036	Common Stock	399,746	$0	399,746	D

Explanation of Responses:

1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

2. The options vest as to 1/4 of the total award on June 2, 2027, and an additional 1/48 of the total award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)